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Highlights:  
 Linezolid interruption occurred in one-third of patients on bedaquiline therapy 
 Anaemia and peripheral neuropathy are the most commonly reported adverse events 
 System-specific toxicities occurred at predictable time frames following treatment 
 HIV co-infection and high bacteria load predispose to linezolid interruption 
 Linezolid interruption does not predispose to having unfavourable treatment outcome 
 
Abstract 
Background 
Treatment outcomes of extensively drug-resistant tuberculosis (XDR-TB) patients are sub-
optimal and treatment options remain limited. Linezolid is associated with improved 
outcomes but also substantial toxicity, and details about the relationship between these are 
lacking from resource-poor HIV-endemic settings.  
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Methods 
We prospectively followed up 63 South African XDR-TB patients (58.7% HIV-infected; 
median CD4 131 cells/µl) between 2014 and 2018. The frequency and severity of linezolid-
associated adverse events and the impact on treatment outcomes were compared between 
linezolid interrupters and non-interrupters. 
Results 
Twenty-two patients (34.9%) discontinued or underwent dose reduction due to presumed 
linezolid-associated toxicity. Anaemia (77.3% versus 7.3%; p<0.001), peripheral neuropathy 
(63.6% versus 14.6%; p=0.003), and optic neuritis (18.2% versus 9.8%; p=0.34) occurred 
more frequently in linezolid interrupters than in non-interrupters. Anaemia, peripheral 
neuropathy, and optic neuritis occurred at a median of 5, 18 and 23 weeks, respectively, after 
treatment initiation. Linezolid interruption was not associated with unfavourable outcomes 
but was strongly associated with HIV co-infection (aHR 4.831 (1.526- 15.297); p=0.007) and 
bacterial load (culture days to positivity; aHR=0.824 (0.732- 0.927); p=0.001). 
Conclusion 
Linezolid-related treatment interruption is common, is strongly associated with HIV co-
infection, and system-specific toxicity occurs within predictable time frames.  These data 
inform the clinical management of patients with drug resistant TB. 
 
Keywords: Drug-resistant tuberculosis, Linezolid, Bedaquiline, Outcome, Treatment 
interruption 
 
Introduction 
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The increasing prevalence of  multidrug resistant tuberculosis (XDR-TB) has become a 
serious public health problem (Dheda et al., 2017). MDR-TB is defined as M. tuberculosis 
resistant to isoniazid and rifampicin, the two most important TB drugs. Treatment outcomes 
for MDR-TB are poor and treatment options are limited. . Extensively drug resistant (XDR-
TB) is defined as MDR-TB with further resistant to a fluoroquinolone and a second line 
injectable drug. Although injectables are no longer frontline treatment for MDR-TB, in this 
manuscript we have retained the term XDR-TB and it was the definition used for the duration 
of the study.Linezolid, usually together with bedaquiline, is now widely used to treat XDR-
TB and fluoroquinolone-resistant TB and is associated with improved culture conversion and 
survival  (Borisov et al., 2017; Guglielmetti et al., 2017; Myungsun Lee et al., 2012; 
Olayanju et al., 2018; Sotgiu et al., 2012; Tang et al., 2015). However, linezolid has 
substantial toxicity and is associated with significant myelosuppression, peripheral 
neuropathy and optic neuropathy (Cox & Ford, 2012; Myungsun Lee et al., 2012; Sotgiu et 
al., 2012). Thus, toxicity often leads to interruption of linezolid (stopping the drug for a 
variable period of time or reducing the dose) in 30 to 60% of patients (Cox & Ford, 2012; M. 
Lee et al., 2012).  
However, details about the specific relationship between the duration of linezolid treatment 
and system-specific toxicity, impact of treatment interruption on outcomes, and effect of HIV 
co-infection are lacking. Moreover, there are very limited data about linezolid toxicity from 
TB and HIV endemic settings.   To address this knowledge gap, we determined the frequency 
of linezolid-associated toxicity, the temporal relationship between linezolid initiation and 
system-specific drug toxicity, and the effect of linezolid interruption (dose reduction or 
discontinuation) on treatment outcomes of XDR-TB patients receiving a bedaquiline-based 
regimen. 
Methods 
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Participants  
We prospectively followed up 63 patients with culture-confirmed XDR-TB between April 
2014 and April 2018. All patients received a bedaquiline-based treatment regimen containing 
linezolid as one of the major components. The patients were admitted to Brooklyn Chest 
Hospital, Cape Town, the XDR-TB treatment centre in the Western Cape province of South 
Africa. Patients’ treatment was directly observed by trained health care workers during 
hospitalisation and after discharge to outpatient treatment centres. Data were captured by a 
trained researcher; relevant information obtained included demographics, clinical details, 
medications received and adverse events. Patients were classified as linezolid interrupters 
(dose reduction or discontinuation) or non-interrupters, and we performed a comparative 
analysis of linezolid interrupters and non-interrupters to expressly interrogate whether this 
interruption adversely impact outcomes, and its potential association with HIV co-infection. 
Ethical approval was obtained from University of Cape Town human research ethics 
committee. 
Diagnosis and medications received  
All the patients had culture isolates with M. tuberculosis strains resistant to isoniazid, 
rifampicin, ofloxacin and a second line injectable anti-TB drug, and met XDR-TB diagnosis 
criteria (WHO, 2006). They all received a treatment regimen based on a backbone of 
Linezolid and bedaquiline. Linezolid was administered at 600mg daily for one year and 
bedaquiline at 400mg daily for two weeks, and then 200mg three times weekly for 22 weeks. 
The other drugs common to most of the patients were clofazimine, levofloxacin, 
pyrazinamide (PZA) and para-amino salicylic acid (PAS). 
Adverse events profiling 
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Adverse events were actively reported by trained health care workers using a standardised 
case report form and were graded according to the modified American National Institute of 
Health Common Terminology of Criteria for Adverse Events. Grades 0 means no adverse 
events; grade 1 means mild adverse event, requiring no intervention; grade 2 means moderate 
adverse event requiring either changing the dose or frequency of the offending drug, or 
prescribing another drug to manage the adverse event; grade 3 means severe adverse event, 
enough to stop the offending drug; grade 4 means life threatening or disabling adverse event; 
grade 5 means death resulting from the adverse event (Trotti et al., 2003). 
Outcomes 
Treatment outcomes were assigned according to an adapted version of the 2013 world health 
organisation definitions and reporting frameworks for TB and, the core research definitions 
for drug-resistant TB clinical trials recommended by Furin et al (Furin et al., 2016; WHO, 
2013). Patients were said to have achieved a favourable outcome if they were cured or 
completed treatment; other treatment outcomes: deceased, lost to follow-up and treatment 
failure, were considered to be unfavourable. 
Statistical analysis 
The effect of linezolid interruption was determined by comparative analysis of demographics, 
clinical characteristics and treatment outcomes. Qualitative and quantitative variables were 
reported in percentages and median (interquartile range; IQR). Quantitative and qualitative 
variables were compared using Mann-Whitney U and chi-square or Fisher’s exact tests 
respectively. Univariate cox proportional hazard model was used to estimate the relationship 
between independent variables (demographic and clinical characteristics), and selected 
outcome variables (mortality, the development of linezolid associated adverse events, 
linezolid interruption, culture conversion and unfavourable outcome). Multivariate models 
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included variables that were significantly associated with outcomes and pre-selected 
variables. A p-value of <0.05 was taken as statistically significant. Kaplan-Meier curves for 
the probability of survival was estimated considering the duration between the day of 
treatment initiation and follow-up censor date. Comparison between strata (HIV-infected vs 
HIV non-infected, linezolid treatment greater than three months vs linezolid treatment less 
than three months) was made using log-rank test. Statistical analysis was done using SPSS 
(Version 25). 
Results  
Demographic and clinical characteristics 
Sixty-three XDR-TB patients met the diagnostic requirements for this study. Demographic 
and clinical characteristics are reported in Table 1. The median age at admission was 37 (IQR 
30-44) years, and 39 (61.9%) were males. Median weight at admission was 51.8 (IQR 46.0-
58.6) kg and patients were on admission for a median of 155 (IQR 102-214) days. 37 (58.7%) 
patients were HIV-infected, the median CD4 count was 131 (56-257) cells/µl at admission, 
and all were on antiretroviral therapy. Patients received a median of 8 (7-8) anti-TB drugs 
with linezolid and bedaquiline being the major components. Drugs used in the regimen are 
outlined in Table 2. Linezolid interruption due to adverse events occurred in 22 (34.9%) 
patients during the course of treatment while the remaining 41 (65.1%) completed one year of 
uninterrupted linezolid therapy. Of the 22 patients who had linezolid interruption, 10 had 
dosage reduction from 600mg to 300mg daily, while 12 had linezolid discontinued.  
Adverse events 
A total of 208 adverse events were reported by 57 (90.5%) patients; a median of 3 (IQR 2-5) 
adverse events were reported in the whole cohort.  33 (52.4%), 45 (71.4%) and 36 (57.1%) 
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patients reported grade 1, grade 2 and grade 3 adverse events, respectively. No patients had 
life-threatening adverse events or died from them. Anaemia (31.7%), peripheral neuropathy 
(31.7%) and body pains (27%) were the most commonly reported adverse events in the whole 
cohort. Comparison of adverse events between linezolid interrupters and non-interrupters are 
outlined in Table 3. Anaemia, peripheral neuropathy and optic neuritis developed a median of 
5 (IQR 4-10) weeks, 18 (IQR 11-24) weeks and 23 (IQR 21-26) weeks, after linezolid 
treatment initiation (Online supplement figure S1). In patients who developed anaemia 
(haemoglobin level< 10g/dl), 62.5% and 87.5% of them had it within eight and twelve weeks 
of treatment initiation, respectively, with a median of 26.1% (IQR 10.4-36.1) drop in baseline 
haemoglobin by 12 weeks of treatment. Table 4 shows the cumulative number of patients that 
developed adverse events with treatment progression. Anaemia (p<0.001) and peripheral 
neuropathy (p=0.003) occurred more frequently in linezolid interrupters. Two of these 
patients received blood transfusion, and two others had nutritional support. 
Although we observed no difference in the proportion of HIV-infected patients (89.2%) who 
reported at least one adverse event compared to the non-infected patients (88.5%), there were 
more cases of linezolid interruption in HIV-infected patients (40.5%) compared to the non-
infected patients (26.9%). Kaplan-Meier estimate also suggested that HIV-infected patients 
are more likely to have linezolid interruption within 18 months of treatment (p=0.005; Figure 
1). 
Multivariate analysis showed that duration of linezolid treatment is an independent predictor 
of linezolid interruption in the whole cohort (HR=0.993; p<0.001). It also suggested that 
HIV-infected patients (HR=4.831; p=0.007), and patients with higher bacteria load (culture 
days to positivity; HR=0.824; p=0.001) had higher probability of linezolid interruption (Table 
5). Kaplan-Meier survival estimate showed no difference in the probability of unfavourable 
outcome between linezolid interrupters and non-interrupters (p=0.59; Online supplementary 
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Figure S2), it also showed that patients who received linezolid for greater than three months 
are more likely to survive (p<0.001; Figure 2). 
 
Discussion 
This is the first prospective study on probable linezolid associated adverse events in XDR-TB 
patients from a TB/HIV endemic country. Our major findings were that linezolid interruption 
is common; the adverse events causing linezolid interruption occur at “predictable” time-
points; HIV co-infection and bacterial burden are associated with linezolid interruption and 
linezolid interruption does not affect treatment outcomes.  
Our study established that the use of linezolid in treatment regimen for XDR-TB, as 
recommended by the WHO is associated with several adverse events, especially peripheral 
neuropathy and anaemia; this is similar to findings from other studies(Agyeman & Ofori-
Asenso, 2016; Park et al., 2006; Zhang et al., 2015). Over one third of patients had linezolid 
interruption in their treatment regimen following the development of an adverse event. 
Adverse events that were likely due to linezolid toxicity occurred within predictable time 
frames. The predictability of these events can inform patient care and guide physicians and 
health care workers in patients management, possibly informing dose adjustment at critical 
time points in a bid to prevent the occurrence or severity of adverse events. 
Several methods to reduce linezolid associated adverse events have been proposed. 
Deliberate reduction in linezolid dosage at specific times in the course of treatment, when 
adverse events are known to develop may mitigate or outrightly prevent the occurrence of 
such adverse events (Anger et al., 2010; Zhang et al., 2015). A shorter treatment regimen has 
also been proposed , following the preparation of suitable protocol, approval by national 
ethics committee and delivery under WHO recommended standards(WHO, 2018). This was 
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corroborated by a study suggesting that linezolid cumulative dose and days of exposure play 
an important role in the development of adverse event (Bolhuis et al., 2015).  Therapeutic 
drug monitoring has been suggested for patients on long-term linezolid treatment, but the cost 
and the rigours involved make it less feasible; a limited sampling strategy which is cheaper, 
less time consuming and more feasible has been proposed to individualise linezolid 
dosing(Alffenaar et al., 2010; Kamp et al., 2017). Recently, a linezolid related adverse events 
predictive score (LAPS) was developed as a tool for clinicians to assess pre-therapeutic risk 
of patients to developing those adverse events(Buzelé et al., 2015). LAPS entails assigning 
scores for certain selected clinical risk factors in patients and grading the summation to 
predict the development of linezolid associated adverse events.  
Yet the effect of linezolid interruption on treatment outcomes remains unclear and has rarely 
been described in HIV-infected XDR-TB patients from endemic countries. In this study, we 
explored the relationship between HIV infection and linezolid interruption in patients with 
drug resistant tuberculosis. We found that HIV co-infection contributed significantly to the 
occurrence of linezolid interruption. This is in keeping with numerous studies that show 
higher adverse event rates and consequent drug withdrawal in HIV-infected compared to the 
un-infected patients (Breen et al., 2006; Mehta et al., 2008; O.S. Michael, 2016). HIV 
infection also contributed to the development of unfavourable outcome, in this study. 
Time to sputum culture positivity in patients has been used over the years as a proxy for 
disease severity(Dominguez-Castellano et al., 2003; Güler, Ünsal, Dursun, AydIn, & Capan, 
2007). In this study, it correlatedsignificantly with linezolid interruption and this may be an 
indication that patients who are more sick at the commencement of therapy are more likely to 
have treatment interruption. Attending physician may be required to monitor them more 
closely and make individualised dosage plan for such patients. 
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There were a few limitations to this study. All the patients in this study were hospitalised in 
the designated treatment centre during the course of treatment, thus, selection bias might have 
affected the findings. However, the programmatic policy at the centre requires all patients to 
be hospitalised at least in the intensive phase of therapy. Given the small sample size, the 
study may not have been sufficiently powered to detect the differences between patients who 
had linezolid interruption and those who did not. This however is arguably one of the 
linezolid original studies available with the highest number of participants. This study was 
conducted in a TB/ HIV endemic setting with a very high enrolment on antiretroviral (ARV) 
therapy; findings may be different in countries with low HIV prevalence or those with low 
ARV coverage.  
In conclusion, linezolid associated system-specific toxicity occurs within predictable time 
frames and it is commonly associated with treatment interruption This prospective study from 
a TB endemic country demonstrates that linezolid interruption does  not negatively impact 
treatment outcomes though larger studies are needed to confirm this finding.  . These data  
inform the  use of linezolid  for DR-TB treatment in TB endemic countries. 
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Number at risk                                                                                           Number at risk 
YES 50 50 50 30 12 2 1  1 
 NO 13 6 6 3 2 2 0  0 
Figure 1 (A): Kaplan-Meier survival estimate for patients who received linezolid for more 
than 3 months in their treatment regimen and (B) for the probability of linezolid continuation 
in HIV-infected patient during an 18 months treatment period. 
  
YES 15 11 8 6 4 0 0 
NO 7 6 4 3 2 0 0 
A B 
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Table 1: Demographic, clinical characteristics and treatment outcomes of XDR-TB patients 
treated with a linezolid-and bedaquiline-based regimen. Data are reflected as number of 
persons (%) unless otherwise stated. 
Variables Patients without 
linezolid interruption 
(n=41) 
Patients with linezolid 
interruption (dose 
reduction or 
discontinuation; n=22) 
p-values 
Gender (Male) 27 (65.9) 12 (54.5) 0.38 
Weight (kg) 53.7(IQR 46.5-60.8) 48.7 (IQR 42.9-54.8) 0.17 
Age (years) 36 (IQR 29-44) 38 (IQR 31.5-46.3) 0.36 
Admission duration 
(days) 
155 (IQR 106-222) 155 (IQR 107-210) 0.71 
Duration of 
linezolid treatment 
(days) 
365 (IQR 181-366) 231.5 (IQR 151-366) <0.001 
HIV-infected 22 (53.7) 15 (68.2) 0.27 
CD4 Count/µl 169 (IQR 55-252) 127 (IQR 56-257) 0.37 
Patients with 
previous TB 
treatment 
21 (51.2) 11 (50) 0.93 
Number of anti-TB 
drugs 
8 (7-8) 7 (7-8) 0.31 
Favourable 
outcome 
(Cured/Completed 
treatment) 
30 (73.2) 15 (68.2) 0.68 
 
Unfavourable 
outcomes 
11 (26.8) 7 (31.8) 
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Table 2: Drugs used in the treatment regimens and the number (%) of patients who received 
them stratified by linezolid interruption 
Drug Patients without 
linezolid interruption 
(n=41) 
Patients with linezolid 
interruption (dose 
reduction or 
discontinuation; n=22) 
p-values 
Linezolid 41 (100) 22 (100) *N/A 
Bedaquiline 41 (100) 22 (100) *N/A 
Clofazimine 40 (97.6) 22 (100) 0.46 
Ethambutol 15 (36.6) 4 (18.2) 0.13 
Ethionamide 11 (26.8) 3 (13.6) 0.23 
Isoniazid 12 (29.3) 8 (36.4) 0.56 
Levofloxacin 40 (97.6) 21 (95.5) 0.65 
Para-aminosalicylic 
acid 
39 (95.1) 21 (95.5) 0.95 
Pyrazinamide 40 (97.6) 21 (95.5) 0.65 
Terizidone 39 (95.1) 20 (90.9) 0.51 
Moxifloxacin 8 (19.5) 2 (9.1) 0.28 
Delamanid 5 (12.2) 3 (13.6) 0.87 
*N/A= Not applicable  
  AC
CE
PT
ED
 M
AN
US
CR
IPT
16 
 
Table 3: Number (%) of patients experiencing adverse events depending on linezolid 
interruption.  
Variables Patients without linezolid 
interruption (n=41) 
Patients with linezolid 
interruption (dose reduction 
or discontinuation; n=22) 
p-values 
Peripheral 
neuropathy 
6 (14.6) 14 (63.6) 0.003 
Anaemia 3 (7.3) 17 (77.3) <0.001 
Arthralgia 6 (14.6) 5 (22.7) 0.42 
Skin reaction 8 (19.5) 8 (36.4) 0.14 
Body pains  11 (26.8) 6 (27.3) 0.97 
Optic neuritis 4 (9.8) 4 (18.2) 0.34 
Dizziness 5 (12.2) 5 (22.7) 0.28 
Dyspepsia 2 (4.9) 1 (4.5) 0.95 
Nausea 4 (9.8) 5 (22.7) 0.16 
Vomiting 7 (17.1) 5 (22.7) 0.59 
Epigastric pain 6 (14.6) 5 (22.7) 0.42 
Diarrhoea 4 (9.8) 2 (9.1) 0.93 
Thyroid dysfunction 3 (7.3) 4 (18.2) 0.19 
Psychosis 3 (7.3) 2 (9.1) 0.81 
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Table 4: Cumulative number (%) of patients that experienced an adverse event (types) with 
increased treatment duration.  
Treatment 
Duration 
Patients that 
developed any 
adverse event 
(n=22) 
Patients that 
developed 
anaemia (n=16) 
Patients that 
developed 
peripheral 
neuropathy (n=13) 
Patients that 
developed 
optic neuritis 
(n=4) 
1 Month  5 (22.7)  5 (31.3) 0 (0) 0 (0) 
2 Months  10 (45.5)  10 (62.5)  2 (15.4) 0 (0) 
3 Months  15 (68.2)  14 (87.5)  6 (46.2) 0 (0) 
4 Months 17 (77.3) 16 (100)  6 (46.2) 0 (0) 
5 Months 18 (81.8) 16 (100)  7 (53.8)  1 (25) 
6 Months 21 (95.5) 16 (100)  10 (76.9)  3 (75) 
9 months 22 (100) 16 (100) 12 (92.3)  4 (100) 
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Table 5: Univariate and multivariate cox proportional hazard model interrogating factors 
associated with unfavourable outcome and linezolid interruption. 
 Unfavourable outcome (n=18) Linezolid interruption (n=22) 
Univariate analysis 
Variable Hazard Ratio 
(95% C.I.) 
p-value Hazard Ratio (95% 
C.I.) 
p-value 
Weight(kg) 0.977 (0.934- 
1.023) 
0.32 0.973 (0.933-1.013) 0.19 
Gender (male) 2.655 (1.024- 
6.889) 
0.05 1.790 (0.758-4.229) 0.18 
Days hospitalized 0.990 (0.982- 
0.997) 
0.008 0.998(0.994-1.002) 0.38 
HIV-infected 1.763 (0.647-
4.806) 
0.27  1.901 (0.768- 4.779) 0.17 
Age (years) 1.011 (0.964- 
1.060) 
0.65 1.025 (0.981-1.071) 0.28 
Previous tuberculosis treatment 1.170 (0.706- 
2.109) 
0.51 1.096 (0.719-1.671) 0.67 
Levofloxacin/Moxifloxacin 
treatment  
0.045 (0.00- 1266) 0.55 1.162 (0.151- 8.908) 0.89 
PZA treatment 3.715 (0.455- 
30.357) 
0.666 2.143 (0.283-16.261) 0.46 
Number of TB drugs 0.975 (0.637- 
1.492) 
0.91 0.898 (0.591-1.366) 0.62 
Smear grade (baseline) 2.064 (0.902- 
4.722) 
0.09 1.287 (0.762- 2.173) 0.35 
#Time to culture positivity in days  0.954 (0.890- 
1.023) 
0.19 0.886 (0.818- 0.961) 0.003 
Duration on linezolid (days) 0.995 (0.992- 
0.998) 
0.03 0.997 (0.994-1.000) 0.02 
Multivariate analysis 
Weight (kg)  1.015 (0.967- 
1.066) 
0.55 0.975 (0.929- 1.024) 0.32 
Gender (male) 1.411 (0.473- 
4.207) 
0.54 1.469 (0.513- 4.210) 0.47 
Duration on linezolid 0.996 (0.991- 
1.000) 
0.05 0.993 (0.989- 0.997) <0.001 
HIV-infected 2.211 (0.645- 
7.575) 
0.21 4.831 (1.526- 15.297) 0.007 
Days hospitalized 0.996 (0.987- 
1.005) 
0.36 N/A* N/A* 
Linezolid interruption 0.981 (0.351- 
2.744) 
0.97 N/A* N/A* 
#Time to culture positivity in days  N/A* N/A* 0.824 (0.732- 0.927) 0.001 
Age N/A* N/A* 1.093 (1.030- 1.160) 0.003 
N/A*=Not applicable, #Baseline sputum sample was used 
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